Amlexanox

Amlexanox (CAS No.: 68302-57-8) is a small-molecule anti-inflammatory and anti-allergic agent widely utilized in biomedical research for investigating immune modulation and inflammatory signaling pathways. Originally developed for the management of atopic conditions such as allergic asthma and rhinitis, and clinically applied as a topical oral paste for recurrent aphthous ulcers, amlexanox has gained significant attention as a selective inhibitor of the non-canonical IκB kinases IKKε and TANK-binding kinase 1 (TBK1), with inhibitory activity observed in the low micromolar range. Mechanistically, it interferes with kinase-mediated signaling cascades involved in innate immunity and metabolic inflammation, and has also been reported to associate with calcium-binding proteins S100A12 and S100A13, thereby modulating fibroblast growth factor 1 release and cytoskeletal dynamics. These properties position amlexanox as a valuable tool compound for studying pathways related to inflammation, metabolic regulation, and immune responses. In experimental settings, it is commonly applied in cell-based assays and preclinical models to dissect kinase-dependent signaling and to evaluate therapeutic hypotheses, with concentrations or dosing regimens adjusted according to specific experimental objectives.